Literature DB >> 23816696

C/EBPα inhibits hepatocellular carcinoma by reducing Notch3/Hes1/p27 cascades.

Yi-Chao Shi1, Hong Zhao, Chuan Yin, Xin Zeng, Qing Zhang, Wen-Ping Xu, Ji Wei, Fei Chen, Wei-Fen Xie.   

Abstract

BACKGROUND AND AIMS: CCAAT/enhancer binding protein α is one of the key transcription factors of the hepatocyte nuclear factors family, which plays a critical role in liver cell proliferation and differentiation. However, the role of CCAAT/enhancer binding protein α in hepatocarcinogenesis remains to be defined.
METHODS: A recombinant adenovirus carrying the C/EBPα gene was constructed to determine its effect on hepatocarcinogenesis in vitro and in vivo.
RESULTS: We demonstrated that overexpression of CCAAT/enhancer binding protein α inhibited the tumourigenicity of Huh7 cells, re-established the expression of certain liver-specific genes and induced G0/G1 arrest. Overexpression of CCAAT/enhancer binding protein α significantly suppressed the proliferation of primary hepatocarcinogenesis cells and tumour associated fibroblasts in vitro. Additionally, intratumoural injection of adenovirus carrying the C/EBPα reduced the growth of subcutaneous hepatocarcinogenesis xenografts in nude mice. Systemic administration of adenovirus carrying the C/EBPα resulted in the eradication of orthotopic liver hepatocarcinogenesis nodules in nude mice. Further, up-regulation of CCAAT/enhancer binding protein α reduced the expression of Notch3, thereby suppressing Hes1 transactivation activity and leading to decreased p27 expression. Overexpression of Hes1 partially abolished the anti-proliferation effect of CCAAT/enhancer binding protein α on Huh7 cells.
CONCLUSION: These results suggested that the effect of CCAAT/enhancer binding protein α on hepatocarcinogenesis is partially through by reducing Notch3/Hes1/p27 cascades and CCAAT/enhancer binding protein α may possess a novel therapeutic potential for human hepatocarcinogenesis.
Copyright © 2013 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C/EBPα; Hepatocellular carcinoma; Hes1; Notch3

Mesh:

Substances:

Year:  2013        PMID: 23816696     DOI: 10.1016/j.dld.2013.03.013

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  4 in total

Review 1.  A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood.

Authors:  A R Lourenço; P J Coffer
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

2.  Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.

Authors:  Vikash Reebye; Kai-Wen Huang; Vivian Lin; Sheba Jarvis; Pedro Cutilas; Stephanie Dorman; Simona Ciriello; Pinelopi Andrikakou; Jon Voutila; Pal Saetrom; Paul J Mintz; Isabella Reccia; John J Rossi; Hans Huber; Robert Habib; Nikos Kostomitsopoulos; David C Blakey; Nagy A Habib
Journal:  Oncogene       Date:  2018-03-07       Impact factor: 9.867

3.  Activation of Notch3 promotes pulmonary arterial smooth muscle cells proliferation via Hes1/p27Kip1 signaling pathway.

Authors:  Yang Song; Yonghong Zhang; Haoxiang Jiang; Yanting Zhu; Lu Liu; Wei Feng; Lan Yang; Yibin Wang; Manxiang Li
Journal:  FEBS Open Bio       Date:  2015-08-12       Impact factor: 2.693

4.  Integration of chronological omics data reveals mitochondrial regulatory mechanisms during the development of hepatocellular carcinoma.

Authors:  J Noé García-Chávez; Verónica R Vásquez-Garzón; Mercedes G López; Saúl Villa-Treviño; Rafael Montiel
Journal:  PLoS One       Date:  2021-08-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.